Photodynamic therapy for prostate cancer: One urologist's perspective

Summary 

Photodynamic therapy (PDT) has slowly found its place in the treatment of human disease. Currently, photodynamic therapy is being explored as a treatment option for localized prostate cancer. PDT for the treatment of prostate cancer will require ablation of both malignant and non-malignant glandular epithelium. Ablation of both malignant and normal epithelium adds a new treatment dimension since traditionally PDT has not targeted normal epithelial tissue. PDT for prostate cancer as currently envisioned will present challenges in terms of in situ monitoring of light, drug concentration, levels and biologic endpoints. The introduction of vascular-targeted photosensitizers fundamentally alters the traditional axioms for successful PDT treatment by obviating the need for “selective” tumor localization. Should clinical trials demonstrate the utility of this approach, patients with organ-confined disease will benefit.

Keywords: Photodynamic therapy, Prostate, Prostate Cancer

Abbreviations: PDT, Photodynamic therapy, PSA, Prostate specific antigen, HpD, Hematoporphyrin derivative, SnET2, Tin etiopurpurin, TOOKAD, palladium-bacteriopheophorbide